Future directions of sickle cell disease research: The NIH perspective

Pediatric Blood and Cancer

Volumn 59, Issue 2, 2012, Pages 353-357

  Hoots, W Keith ^a   Shurin, Susan B ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Global health; Research; Sickle cell disease

Indexed keywords

BIOLOGICAL MARKER; HEMOGLOBIN; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENOMICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; INFLAMMATION; MOLECULAR PATHOLOGY; NEWBORN SCREENING; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SURVIVAL; THROMBOSIS; UNITED STATES; VACCINATION;

ADULT; ANEMIA, SICKLE CELL; BIOMEDICAL RESEARCH; CHILD; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

EID: 84862243355     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24180     Document Type: Review

References (1)

1. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicenter, randomized, controlled trial (BABY HUG). Lancet 2011; 377: 1663- 1672.